OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
(2022) 2022 World Conference on Lung Cancer — Location: (Austria) Vienna (6.August.2022)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- INTRODUCTION : The combination of IO-CT has become the standard of care for patients with aNSCLC with a low or intermediate programmed death-ligand 1 (PD-L1) expression (<50%), and an option for patients with high PDL1 (≥50%) expression. There are no data available on the subsequent line (L2) outcomes after IO-CT. We aimed to assess the outcomes of various L2 treatments after IO-CT in aNSCLC. [...]
- Affiliations
Citations
Auclin, E., Benitez-Montanez, J., Gorria, T., Garcia-Campelo, R., Dempsey, N., Pinato, D. J., Reyes, R., Albarran, V., Dall’ollio, F., Soldato, D., Hendriks, L., Aboubakar Nana, F., Tonneau, M., Lopez-Castro, R., Nadal, E., Katsandjian, S., Blanc-Durand, F., Fabre, E., Castro, N., et al. (2022). OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC). Journal of Thoracic Oncology, 17(9), S22. https://doi.org/10.1016/j.jtho.2022.07.043 (Original work published 2022)